CN119584873A - Composition and use thereof - Google Patents
Composition and use thereof Download PDFInfo
- Publication number
- CN119584873A CN119584873A CN202380052128.XA CN202380052128A CN119584873A CN 119584873 A CN119584873 A CN 119584873A CN 202380052128 A CN202380052128 A CN 202380052128A CN 119584873 A CN119584873 A CN 119584873A
- Authority
- CN
- China
- Prior art keywords
- composition
- species
- bifidobacterium
- enteral
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract description 131
- 239000006041 probiotic Substances 0.000 abstract description 29
- 235000018291 probiotics Nutrition 0.000 abstract description 29
- 235000013406 prebiotics Nutrition 0.000 abstract description 26
- 239000000835 fiber Substances 0.000 abstract description 24
- 230000007958 sleep Effects 0.000 abstract description 22
- 230000003860 sleep quality Effects 0.000 abstract description 17
- 241000186000 Bifidobacterium Species 0.000 abstract description 15
- 241000186660 Lactobacillus Species 0.000 abstract description 15
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 15
- 206010022437 insomnia Diseases 0.000 abstract description 15
- 206010006326 Breath odour Diseases 0.000 abstract description 13
- 230000037075 skin appearance Effects 0.000 abstract description 5
- 230000001965 increasing effect Effects 0.000 abstract description 4
- 230000000529 probiotic effect Effects 0.000 description 24
- 239000000843 powder Substances 0.000 description 17
- 230000001332 colony forming effect Effects 0.000 description 13
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 235000016709 nutrition Nutrition 0.000 description 11
- 235000015203 fruit juice Nutrition 0.000 description 8
- 229920001542 oligosaccharide Polymers 0.000 description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 5
- 229920002498 Beta-glucan Polymers 0.000 description 5
- 208000032139 Halitosis Diseases 0.000 description 5
- 206010062519 Poor quality sleep Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical group C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 240000003394 Malpighia glabra Species 0.000 description 4
- 235000014837 Malpighia glabra Nutrition 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 description 3
- -1 glycosyl Sucrose Chemical compound 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229960000511 lactulose Drugs 0.000 description 3
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019722 synbiotics Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000004617 sleep duration Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 241000796654 Axos Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000185999 Bifidobacterium longum subsp. longum Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 150000004783 arabinoxylans Chemical class 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000020245 plant milk Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 235000021269 warm food Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
披露了用于预防或治疗失眠、改善睡眠质量、改善皮肤外观、减少口臭并且增加睡眠放松、改善睡眠质量的组合物。特别地，这些组合物包含选自下组的益生菌，该组包含：乳酪杆菌属物种、双歧杆菌属物种或其组合；以及任选地益生元纤维。Compositions for preventing or treating insomnia, improving sleep quality, improving skin appearance, reducing bad breath, and increasing sleep relaxation, improving sleep quality are disclosed. In particular, these compositions comprise probiotics selected from the group consisting of: Lactobacillus species, Bifidobacterium species, or a combination thereof; and optionally prebiotic fibers.
Description
Technical Field
The present invention relates to a composition for preventing or treating insomnia, improving skin appearance, reducing halitosis, and increasing sleep relaxation and improving sleep quality.
Background
The sleeping time varies from person to person. Seven to eight hours per night are considered necessary for most adults. As aging progresses, the internal sleeping biological clock begins to lose consistency. Thus, elderly people tend to feel tired earlier in the evening, wake earlier in the morning, resulting in less overall sleep and increased risk of cognitive decline. Elderly people suffering from alzheimer's disease, dementia or other neurodegenerative diseases experience more severe changes in sleep driving.
More and more adults experience short-term acute insomnia lasting days or weeks at certain moments in life. This is typically the result of a stress or trauma event. However, some people suffer from long-term chronic insomnia, which may itself be a major problem, and may be associated with other medical conditions or medications.
The data show that over 3 hundred million chinese experience poor sleep quality, sleep disorders or insomnia. Individuals with poor sleep quality or insomnia often feel tired after waking up and have a negative impact on energy levels, mood and overall health, performance and quality of life.
A large number of individuals with poor sleep quality and/or insomnia motivate the consumption of sleep aid products. In recent years, various types of sleep monitoring and support software have been subsequently brought on-line at the primary APP store. In addition, latex pillows, sleep aids, aromatherapy lamps, melatonin, sleep soft sweets, etc. are often used to aid sleep.
CN104187613 discloses a nutritional formula for insomnia, which comprises traditional Chinese medicine, probiotics, water-soluble prebiotic fiber and the like.
CN107496850 discloses a preparation for regulating intestinal microecology with ginseng to tranquilize the mind and aid sleep.
CN107874251 discloses an eight delicacies probiotic composition comprising 1-9 parts of a chinese herbal extract, 0.01-2 parts of a food grade probiotic and 0.1-5 parts of a prebiotic.
Adult, especially elderly people, are more likely to suffer from poor sleep quality due to various causes such as depression caused by work pressure, activity restriction, interpersonal disputes, etc. However, people are reluctant to seek drug treatment. Thus, there remains a need for improved nutritional intervention to induce relaxation and treat insomnia in a simple and convenient manner.
Disclosure of Invention
In a study for more than 200 adults, the inventors observed that sleep induction and quality, mood were significantly improved and psychological stress was reduced when a composition comprising a combination of prebiotic soluble fiber and probiotic bacterial strain was administered to a subject. Unexpectedly, this improvement was observed within 7 days of the start of administration of the composition according to the invention.
Accordingly, in one aspect, the present invention relates to a composition for use in the prevention and/or treatment of insomnia in a human subject, the composition comprising:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising Lactobacillus species, bifidobacterium species or a combination thereof, and optionally,
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
In a second aspect, the present invention relates to a non-therapeutic method of improving sleep quality, and/or inducing and/or enhancing pre-sleep relaxation, the method comprising administering to a human subject in need thereof a composition, wherein the composition comprises:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising a Lactobacillus species, a Bifidobacterium species, or a combination thereof, and optionally
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
Herein, induction and/or enhancement of pre-sleep relaxation is compared to a human subject not administered the composition according to the invention. Individual experiences may be assessed by professional questionnaires (including digital questionnaires) or determined by mental and psychiatric care professionals.
Furthermore, the inventors have unexpectedly observed a significant improvement in skin appearance and condition, and a reduction in bad breath.
In a third aspect, the present invention relates to a non-therapeutic method of reducing halitosis, the method comprising administering to a human subject in need thereof a composition, wherein the composition comprises:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising a Lactobacillus species, a Bifidobacterium species, or a combination thereof, and optionally
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
Halitosis reduction is defined herein as compared to a subject not administered a composition according to the invention. Individual sensations can be assessed by a professional questionnaire or determined by a dental care professional.
In a fourth aspect, the present invention relates to a non-therapeutic method of improving the appearance and texture of skin, the method comprising administering to a human subject in need thereof a composition, wherein the composition comprises:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising a Lactobacillus species, a Bifidobacterium species, or a combination thereof, and optionally
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
Improvement in skin appearance and texture is defined herein as compared to a subject not administered a composition according to the invention. The individual experiences may be assessed by a professional questionnaire or determined by a skin care professional (e.g., a cosmetologist).
In a fifth aspect, the present invention relates to a composition comprising:
i. At least 40wt.% carbohydrate based on the total weight of the composition,
Not less than 85wt.% of prebiotic soluble fiber based on the total weight of carbohydrate,
10 3 To 10 12 colony forming units/g of at least one probiotic of the composition, the at least one probiotic being selected from the group comprising Lactobacillus species, bifidobacterium species or a combination thereof
Wherein the composition does not comprise lactose.
In all aspects of the invention, the composition is preferably a synbiotic composition.
As defined herein, the composition is an enteral composition, preferably an oral composition.
Detailed Description
"Probiotic" means a microbial cell preparation or microbial cell component that has a beneficial effect on the health or well-being of a host. (SALMINEN S, ouwehand A.Benno Y et al, '' Probiotics: how should they be defined [ Probiotics: how they should be defined ] '' Trends Food ScL Technol [ food technology trend ] 1999:10107-10).
As used herein, "synbiotics" refers to compositions comprising a combination of probiotic microorganisms and prebiotic components.
"Preventing" as used herein refers to reducing the likelihood of developing a disorder or symptoms associated with the disorder in a subject in need thereof or particularly at risk of developing the disorder or symptoms. As used herein, "treatment" refers to reducing, alleviating, or completely eliminating symptoms associated with certain conditions that cause pain or discomfort to humans.
"Insomnia" is a common sleep disorder characterized by difficulty falling asleep, difficulty maintaining sleep, or causing the affected subject to wake prematurely and fail to fall asleep again, and unsatisfactory rates of deep sleep or restorative sleep. The induction of pre-sleep relaxation improves sleep quality and duration, helping to increase the overall sensation of getting a rest after sleep. Diagnosis and assessment may be performed by a general practitioner or medical professional for sleep and related conditions.
As used herein, "sleep quality" refers to quantitative aspects of sleep, such as sleep duration, sleep latency or number of awakenings, as well as subjective aspects, such as depth or peace of sleep. Sleep quality may be determined by the Pittsburgh sleep quality index (Pittsburgh Sleep Quality Index) (Buysee et al, "The Pittsburgh Sleep Quality Index: a new instrument for PSYCHIATRIC PRACTICE AND RESEARCH Pittsburgh sleep quality index: new tools for psychiatric practice and research ]". Psych Res [ psychiatric research ],28,193-213.1989).
Herein, improving sleep quality, and/or inducing and/or enhancing pre-sleep relaxation is compared to a human not taking a nutritional composition comprising a and b (i.e., not taking a composition or taking another composition not comprising a and b). Thus, the improvement of a human taking a nutritional composition comprising a and b is increased by ≡2%, preferably ≡5%, more preferably ≡50%, even more preferably ≡65%, compared to a human not taking a nutritional composition comprising a and b (i.e. not taking a composition or taking another composition not comprising a and b). In particular, if the improvement in a human not taking a nutritional composition comprising a and b (or taking another composition not comprising a and b) is M and the improvement compared to a human taking a nutritional composition comprising a and b is N, (N-M)/N x 100% is the percentage of increase thereof.
"Halitosis" (bad breath or bad breath) is a condition characterized by oral malodor and is not necessarily associated with oral and dental diseases. Halitosis may be of intra-oral or extra-oral origin. Extraoral (non-oral) bad breath may be of gastrointestinal origin. The inventors have unexpectedly observed a reduction in bad breath in subjects administered the composition according to the invention. Without wishing to be bound by any theory, it is hypothesized that the composition according to the invention prevents dysbiosis in the gastrointestinal tract, thereby eliminating the extraoral cause of bad breath.
By "skin appearance and texture" is meant an improved skin feel after administration of the composition according to the invention. In particular, the inventors have unexpectedly observed a significant improvement in the appearance of skin and a reduction in the appearance of enlarged skin pores in adults taking the compositions of the present invention.
In some jurisdictions, the present invention is defined as a method of preventing and/or treating insomnia in a human subject, the method comprising administering to the human subject a composition comprising:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising a Lactobacillus species, a Bifidobacterium species, or a combination thereof, and optionally
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
In other jurisdictions, the present invention is defined as the use of a composition in the manufacture of a composition for preventing and/or treating insomnia in a human subject, the composition comprising:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising a Lactobacillus species, a Bifidobacterium species, or a combination thereof, and optionally
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
In a further jurisdiction, the present invention is defined as a non-therapeutic method of preventing and/or treating insomnia in a human subject, the composition comprising:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising a Lactobacillus species, a Bifidobacterium species, or a combination thereof, and optionally
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
Preferably, the prophylaxis and/or treatment is compared to a human not taking a nutritional composition comprising a and b (i.e. not taking a composition or taking another composition not comprising a and b). Thus, a human taking a nutritional composition comprising a and b increases by ≡2%, preferably ≡5%, more preferably ≡50%, even more preferably ≡65% improvement in preventing and/or treating insomnia (including poor sleep quality) compared to a human not taking a nutritional composition comprising a and b (i.e. not taking a composition or taking another composition not comprising a and b). In particular, if the improvement in a human not taking a nutritional composition comprising a and b (or taking another composition not comprising a and b) is M and the improvement compared to a human taking a nutritional composition comprising a and b is N, (N-M)/N x 100% is the percentage of increase thereof.
Probiotics
Preferably, the composition comprises from 10 3 to 10 12 colony forming units per gram of the composition of at least one probiotic, more preferably from 10 4 to 10 10 colony forming units per gram of the composition of at least one probiotic selected from the group comprising Lactobacillus species, bifidobacterium species or combinations thereof.
In one embodiment, the composition comprises from 1wt.% to 20wt.% of the at least one probiotic based on the dry weight of the composition, more preferably from 3wt.% to 15wt.% of the at least one probiotic based on the dry weight of the composition.
In another embodiment, the composition comprises 25-250mg of at least one probiotic per gram of composition, more preferably 50-150mg of at least one probiotic per gram of composition.
The daily dose of at least one probiotic in the composition according to the invention is an amount of 10 3 to 10 12 colony forming units, preferably 10 8 to 10 11 colony forming units.
In a preferred embodiment of the invention, the composition comprises at least one species of the genus Lactobacillus. Preferably the Lactobacillus species present in the composition is selected from the group comprising Lactobacillus paracasei, lactobacillus acidophilus, lactobacillus muriluz, lactobacillus reuteri, lactobacillus rhamnosus or a mixture thereof. Preferably, the probiotic comprises a paracasei subspecies paracasei, more preferably a paracasei subspecies paracasei CRL 431.
The composition may comprise at least one bifidobacterium species. Preferred bifidobacterium species include bifidobacterium adolescentis, bifidobacterium longum subspecies longum (Bifidobacterium longum subsp. Longum), bifidobacterium infantis subspecies, bifidobacterium pseudolongum, bifidobacterium bifidum, bifidobacterium lactis, bifidobacterium animalis subsp. Lactis, bifidobacterium breve, and mixtures thereof. In a preferred embodiment, the bifidobacterium species is bifidobacterium lactis BB12 (deposited with the german collection of microorganisms and cell cultures (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, DSMZ) under accession No. DSM 15954, commercially available from hansen company (CHRISTIAN HANSEN company of Denmark) of denmark, under the trademark BB12.
In a particularly preferred embodiment of the invention, the composition comprises at least one lactobacillus species and at least one bifidobacterium species. More preferably, the composition comprises a mixture of a sub-cheese species CRL 431 of lactobacillus paracasei and bifidobacterium lactis BB 12.
Prebiotic fiber
The composition comprises a carbohydrate, including a prebiotic fiber.
Preferably, the composition comprises 11% by weight or more of the prebiotic fibers, more preferably 30% by weight or more, even more preferably 40% by weight or more, and even more preferably 60% to 90% by weight of the prebiotic fibers, based on the total weight of the composition.
Preferably, the total carbohydrate is present in an amount ranging from 40wt.% to 98wt.% by weight of the total composition, more preferably from 50wt.% to 95wt.% by weight of the total composition.
Carbohydrates as used herein include sugars and sugar derivatives, monosaccharides and complex sugars, and sugar-rich components. Preferably, the composition comprises a sugar-rich ingredient, such as honey powder, juice powder, etc., preferably the composition comprises 1wt% to 15wt%, preferably 2wt% to 13wt% honey powder based on the total weight of the composition. The composition may further comprise 1wt% to 10wt% fruit juice powder, more preferably 2wt% to 8wt% fruit juice powder based on the total weight. The preferred fruit juice powder is acerola (acerola) fruit juice powder.
In a preferred embodiment, the composition does not comprise lactose and milk-derived carbohydrates, preferably the composition does not comprise lactose.
Preferred prebiotics are Sialylated Oligosaccharides (SOS), fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), isomalto-oligosaccharides (IMO), xylo-oligosaccharides (XOS), arabinoxylans (AXOS), mannooligosaccharides (MOS), soy oligosaccharides, glycosyl Sucrose (GS), lactulose oligosaccharides (LS), sialyllactose (SL), fucosyllactose (FL), lactose-N-neotetraose (LNNT), lactulose (LA), palatinose oligosaccharides (PAO), malto-oligosaccharides, gums and/or hydrolysates thereof, pectins, starches and/or hydrolysates thereof.
The prebiotic fibers are preferably soluble prebiotic fibers. "soluble prebiotic fibers" (also referred to herein as non-digestible fibers) beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon, thereby improving host health. Such components are non-digestible in that they are not disintegrated and absorbed in the stomach or small intestine and thus enter the colon intact, where they are selectively fermented by beneficial bacteria.
Preferred soluble prebiotic fibers are selected from fructooligosaccharides, inulin, galactooligosaccharides, beta-glucan (preferably yeast or oat beta-glucan, more preferably oat beta-glucan) or combinations thereof. In a particularly preferred embodiment, the composition comprises at least one of inulin, fructooligosaccharides and oat β -glucan, more preferably the composition comprises inulin, fructooligosaccharides and oat β -glucan. Commercially available sources include short chain fructooligosaccharides (e.g., under the trademarkProducts sold) and inulin (e.g. under the trademarkProducts for sale).
In a further aspect, the present invention relates to a composition comprising:
i. at least 40wt.% carbohydrate based on the total composition,
Not less than 85wt.% of prebiotic soluble fiber based on the total weight of carbohydrate,
10 3 To 10 12 colony forming units/g of at least one probiotic of the composition, the at least one probiotic being selected from the group comprising Lactobacillus species, bifidobacterium species or a combination thereof
Wherein the composition does not comprise lactose.
Preferably, the composition comprises 45wt.% to 95wt.% carbohydrate based on the total composition, more preferably 50wt.% to 80wt.%, even more preferably at least 70wt.% carbohydrate.
The composition preferably comprises at least 90wt.% prebiotic soluble fiber, more preferably at least 95wt.% prebiotic soluble fiber, even more preferably at least 98wt.% prebiotic soluble fiber, based on the total weight of carbohydrate.
In preferred embodiments, the composition comprises from 0wt.% to 15wt.% lipid based on the total composition, preferably less than 10wt.% lipid based on the total composition, more preferably less than 5wt.% lipid based on the total composition. In particularly preferred embodiments, the composition is substantially free of lipids, e.g., no added lipids are present in the composition, and only trace amounts of lipids present by other ingredients can be detected.
According to a preferred embodiment, the composition comprises 1% to 15% by weight of honey powder, preferably 2% to 13% by weight of honey powder, based on the total weight of the composition.
The composition may further comprise 1wt% to 10wt% fruit juice powder, more preferably 2wt% to 8wt% fruit juice powder based on the total weight. The preferred fruit juice powder is acerola (acerola) fruit juice powder.
Use and application
It has surprisingly been found that the composition of the present invention significantly improves pre-sleep relaxation, reduces psychological stress, improves mood in the adult to whom the composition is administered. In addition, skin dullness and pore size are improved, and bad breath is significantly reduced.
Preferably, the human subject is selected from infants, adolescents or adults. Thus, the composition according to the invention is for administration to humans older than 3 years, preferably older than 6 years, more preferably older than 12 years, more preferably older than 16 years.
In a particularly preferred embodiment, the human subject is an adult having an age of greater than 18 years, preferably greater than 30 years, more preferably greater than 45 years, even more preferably greater than 55 years.
The composition is preferably administered to a human subject in a fasting state, preferably at least 8 hours, more preferably 10-14 hours space-time abdominal state. For example, the composition may be administered in the morning, for example 8 hours after the last meal or evening meal. Preferably, the composition is administered in a fasting state before 7 o' clock in the morning.
Preferably, the composition is administered once daily. The composition is preferably administered for a period of at least 7 days, more preferably at least 14 days, even more preferably at least 30 days.
The composition of the invention is preferably a powder or a ready-to-drink beverage, preferably a powder. The powder is preferably reconstituted in water or a liquid food product (e.g. warm water). However, the powder is suitable for reconstitution in animal or plant milk, beverages, yoghurt, soups, cereals, warm or cold foods etc. The compositions may also be present in liquid suspensions, tablets, chewing gums, candies, nutritional supplements and the like.
The invention is described herein by the following illustrative, non-limiting examples.
Examples
Example 1
The synbiotic supplement according to the invention can be prepared by dry blending. The compositions are shown in table 1.
TABLE 1
Example 2
A study was performed on healthy volunteers (n=209) comprising the administration of the composition according to example 1 for a period of 14 days. Human volunteers are between 40-60 years of age (average 49 years), with 49% being male participants and 51% female participants.
Prior to the start of the study, volunteers were asked to use questionnaires to evaluate different parameters of their health status. It is recommended that the product according to example 1 be taken in the morning and therefore diluted in water at about 30 ℃ with a minimum of 8 hours on an empty stomach. On days 7 and 14, volunteers were asked to re-evaluate health status. The percentage of study subjects who observed the presence of the given parameters is provided on "day 0". The percentage improvement observed is shown in the columns at day 7 and day 14. The results are shown in table 2 below.
TABLE 2
Claims (23)
1. An enteral composition for use in the prevention and/or treatment of insomnia or sleep disorders in a human subject,
The composition comprises:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising a Lactobacillus species, a Bifidobacterium species, or a combination thereof, and optionally,
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
2. Enteral composition according to claim 1, wherein the daily dose of the at least one probiotic is from 10 3 to 10 12 colony forming units, preferably from 10 8 to 10 11 colony forming units.
3. The enteral composition according to any one of the preceding claims, wherein the composition does not comprise lactose.
4. Enteral composition according to any one of the preceding claims, wherein the composition comprises at least one species of the genus lactobacillus, preferably selected from the group consisting of lactobacillus paracasei, lactobacillus acidophilus, lactobacillus murinus, lactobacillus reuteri, lactobacillus rhamnosus or mixtures thereof.
5. The enteral composition according to any one of the preceding claims, wherein the lactobacillus species is lactobacillus paracasei, preferably lactobacillus paracasei subspecies paracasei, more preferably lactobacillus paracasei subspecies CRL 431.
6. Enteral composition according to any one of the preceding claims, wherein the composition comprises at least one bifidobacterium species, preferably selected from the group consisting of bifidobacterium adolescentis, bifidobacterium longum subspecies longum, bifidobacterium infantis subspecies longum, bifidobacterium bifidum, bifidobacterium lactis, bifidobacterium breve and mixtures thereof.
7. Enteral composition according to any one of the preceding claims, wherein the bifidobacterium species is bifidobacterium lactis, preferably bifidobacterium lactis BB12.
8. Enteral composition according to any one of the preceding claims, wherein the composition comprises lactobacillus species and bifidobacterium species.
9. Enteral composition according to any one of the preceding claims, wherein the prebiotic fiber, preferably the soluble prebiotic fiber, is selected from fructooligosaccharides, inulin, galactooligosaccharides, β -glucan or combinations thereof.
10. The enteral composition according to any one of the preceding claims, wherein the composition is administered to a human subject in a fasting state.
11. The enteral composition according to any one of the preceding claims, wherein the empty stomach is at least 8 hours, preferably 10-14 hours.
12. Enteral composition according to any one of the preceding claims, wherein the human subject is an adult, preferably an adult of > 30 years old.
13. The enteral composition according to any preceding claim, wherein the composition is administered once daily.
14. Enteral composition according to any one of the preceding claims, wherein the composition is administered for a period of at least 7 days, preferably at least 14 days.
15. Enteral composition according to any one of the preceding claims, wherein the composition is a powder, preferably a powder reconstituted in warm water.
16. Enteral composition according to any one of the preceding claims, wherein the prophylactic and/or therapeutic improvement is ≡2%, preferably ≡5%, compared to humans not taking nutritional compositions comprising a and b.
17. A non-therapeutic method of improving sleep quality, and/or inducing and/or enhancing pre-sleep relaxation, the method comprising administering to a human subject in need thereof an enteral composition, wherein the composition comprises:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising Lactobacillus species, bifidobacterium species or a combination thereof, and
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
18. The non-therapeutic method of claim 17, wherein the improvement and/or enhancement is greater than or equal to 2%, preferably greater than or equal to 5% relative to a human not taking the nutritional composition comprising a and b.
19. A non-therapeutic method of reducing halitosis, the method comprising administering to a human subject in need thereof an enteral composition, wherein the composition comprises:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising Lactobacillus species, bifidobacterium species or a combination thereof, and
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
20. A non-therapeutic method of improving the appearance and texture of skin, the method comprising administering to a human subject in need thereof an enteral composition, wherein the composition comprises:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising Lactobacillus species, bifidobacterium species or a combination thereof, and
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
21. An enteral composition comprising at least one compound, the enteral composition comprises:
i. at least 40wt.% carbohydrate based on the total composition,
Not less than 85wt.% of prebiotic soluble fiber based on the total weight of carbohydrate,
10 3 To 10 12 colony forming units/g of at least one probiotic of the composition, the at least one probiotic being selected from the group comprising Lactobacillus species, bifidobacterium species or a combination thereof
Wherein the composition does not comprise lactose.
22. Use of a composition according to any one of claims 1 to 16 in the manufacture of an enteral product for the prevention and/or treatment of insomnia or sleep disorders in a human subject, the composition comprising:
a.10 3 to 10 12 colony forming units/g of the composition, the at least one probiotic being selected from the group comprising a Lactobacillus species, a Bifidobacterium species, or a combination thereof, and optionally,
B. And 11wt% or more of prebiotic fiber based on the total weight of the composition.
23. The use of claim 22, wherein the prophylactic and/or therapeutic improvement is ≡2%, preferably ≡5% compared to humans not taking the composition comprising a and b.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022099108 | 2022-06-16 | ||
| CNPCT/CN2022/099108 | 2022-06-16 | ||
| PCT/CN2023/098264 WO2023241390A1 (en) | 2022-06-16 | 2023-06-05 | Compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119584873A true CN119584873A (en) | 2025-03-07 |
Family
ID=89192112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380052128.XA Pending CN119584873A (en) | 2022-06-16 | 2023-06-05 | Composition and use thereof |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN119584873A (en) |
| AU (1) | AU2023293647A1 (en) |
| WO (1) | WO2023241390A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO430496A0 (en) * | 1996-12-19 | 1997-01-23 | Arnott's Biscuits Limited | Prebiotics and probiotics |
| AU2006235307B2 (en) * | 2005-04-08 | 2011-07-14 | Alimentary Health Ltd | Methods of use of orally administered probiotic Bifidobacteria for human beauty benefits |
| CN101095698B (en) * | 2006-06-26 | 2010-12-01 | 青岛东海药业有限公司 | Use of Clostridium Butyricum for preventing and treating foetid faeces toxin syndrome and disease |
| CN106860483A (en) * | 2017-01-06 | 2017-06-20 | 家家乐购（北京）科技有限公司 | Probiotics complex composition and application containing Bifidobacterium and lactobacillus acidophilus |
| CN108244655A (en) * | 2018-02-02 | 2018-07-06 | 云南中京国建投资有限公司 | A kind of tranquilizing the mind, antidepressant symphysis unit composition and its preparation and application |
| CN108671135B (en) * | 2018-08-01 | 2021-06-08 | 山东神农医院管理有限公司 | Traditional Chinese medicine probiotic compound for conditioning insomnia and depression |
| CN110051003A (en) * | 2019-04-24 | 2019-07-26 | 广州能靓生物技术有限公司 | A kind of compound probiotic composition and its application |
-
2023
- 2023-06-05 CN CN202380052128.XA patent/CN119584873A/en active Pending
- 2023-06-05 WO PCT/CN2023/098264 patent/WO2023241390A1/en active Application Filing
- 2023-06-05 AU AU2023293647A patent/AU2023293647A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023293647A1 (en) | 2025-01-23 |
| WO2023241390A1 (en) | 2023-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6796070B2 (en) | Foods and drinks containing indigestible components and hydrogen gas producing agents in the large intestine | |
| TW201029583A (en) | A nutritional composition comprising probiotics and improving sleep patterns | |
| MX2008011450A (en) | Synbiotic mixture. | |
| CN103415297A (en) | A nutritional composition comprising fiber and probiotics for reducing stress-related intestinal symptoms | |
| KR20140131505A (en) | Lactobacillus reuteri DSM 17938 for the development of cognitive function | |
| EP3777869B1 (en) | Sleep-promoting composition, and medicinal composition and food and beverage composition using said sleep-promoting composition | |
| Anilkumar et al. | Role of friendly bacteria in oral health-a short review. | |
| CN103415295A (en) | Fiber and Probiotics to Reduce Stress-Related Bowel Symptoms | |
| TW202027619A (en) | Sleep-improving compositions | |
| CN103415296A (en) | Fiber and probiotics for reducing intestinal symptoms related to chronic stress | |
| CN115226773A (en) | Composite probiotic sleep-aiding solid beverage and preparation method thereof | |
| Horvath et al. | Probiotics, prebiotics, and dietary fiber in the management of functional gastrointestinal disorders | |
| Tulk et al. | Daily consumption of a synbiotic yogurt decreases energy intake but does not improve gastrointestinal transit time: a double-blind, randomized, crossover study in healthy adults | |
| CN119584873A (en) | Composition and use thereof | |
| EP4494695A1 (en) | Composition for controlling proliferation of bacterium in intestine, and use thereof | |
| KR20110112803A (en) | Therapeutics and treatment of arousal related to snoring and respiratory effort during sleep | |
| JP7057039B2 (en) | Agents for preventing or ameliorating dementia and compositions containing them | |
| WO2021111982A1 (en) | Agent for prevention or remediation of stress disorders and composition containing same | |
| EP2323675B1 (en) | Compositions comprising lactobacillus casei cncm i-1518 (dn-114001) for prevention or treatment of an upper respiratory tract infection in smokers | |
| CN116349815A (en) | Production formula of viable bacteria type probiotic solid beverage capable of regulating intestinal flora | |
| CN112401180A (en) | Natural fruit powder synbiotics buccal tablets and preparation method thereof | |
| CN102917716A (en) | Nutritional composition for western blotting | |
| US9937213B2 (en) | Composition comprising L. rhamnosus GG | |
| CN109010356A (en) | Adjust intestinal flora and the anti-composition to treat constipation and its application | |
| JP7646287B2 (en) | Serotonin secretion enhancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |